Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Viking Therapeutics (NasdaqCM:VKTX) saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

Shares of Viking Therapeutics (VKTX) are moving lower in pre-market trading after Eli Lilly (LLY) announced topline Phase 3 results from ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock ...

BTIG highlights “some of the most compelling reasons” to own Viking Therapeutics (VKTX) after news from Pfizer (PFE) on the latter’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Year to date, shares of VKTX and GPCR have plunged 38.9% and 30.1%, respectively, compared with the industry’s 6.4% decline. Image Source: Zacks Investment Research VKTX is currently evaluating ...